INTRODUCTION
As consumers of health care and stakeholders in clinical research, the importance of patients' "real-world" insights has led to a burgeoning movement to engage patients in health care decision-making, quality improvement initiatives and more recently, research. The body of literature speaks to a need to clearly define the scope of "meaningful patient engagement" and how it can be effectively implemented.gaps remain on building an effective engagement infrastructure to address power differentials for patients joining research teams, as well as providing and testing engagement tools, role descriptions, and resources to aid in this revisioning of patient-centered outcomes research (PCOR). 9, 10 Founded in 2001, Oregon Community Health Information Network (OCHIN) is a nonprofit, community-based health information technology collaborative that serves 97 health systems (Federally Qualified Health Centers, community health centers [CHCs] , critical access hospitals, and rural hospitals) in 18 states across the nation, linking 618 clinics with 4927 providers serving > 2.2 million patients [11] [12] [13] [14] [15] in 1 common electronic health record. OCHIN leads the Accelerating Data Value Across a National Community Health Center Network (ADVANCE) clinical data research network (CDRN) in partnership with Health Choice Network and Fenway Health. The network reaches 23 states and is the largest clinical dataset on the safety net in the nation. It has a truly national footprint, and engages patients, clinicians, health systems, and researchers.
CHCs, which comprise the majority of the ADVANCE network, have a long history of engaging patients on their community-based governing boards. 16 Before ADVANCE, OCHIN researchers had developed mechanisms (eg, community retreats, focus groups, patient interviews, and project advisory councils) for engaging patients and communities for specific research projects. However, OCHIN had not explicitly structured research governance in a way that provided ongoing structure for direct patient engagement across projects and organizational services. 17 Through ADVANCE, our network is able to build on the CHC tradition of patient engagement in a new era of PCOR.
Driven by a goal to fundamentally change the health research landscape, the Patient-Centered Outcomes Research Institute (PCORI) funded several research networks, like ADVANCE, to enable big data comparative effectiveness research that is driven by patient priorities. [18] [19] [20] In this paper, we describe and reflect on our patient stakeholder groups, our engagement framework and our experience in engaging patients and other stakeholders in research, from generating proposal ideas to disseminating findings.
DESCRIPTION OF ENGAGEMENT GROUPS AND ACTIVITIES
The ADVANCE network began phase I in 2014 through an award from PCORI as a partner in their development of PCORnet: The National Patient-Centered Clinical Research Network. ADVANCE specifically contributes to this network as it brings vulnerable and diverse Federally Qualified Health Center patient populations to PCORnet's PCOR. PCORI defines PCORnet as "a large, highly representative, national 'network of networks' that collects data routinely gathered in a variety of health care settings, including hospitals, doctors' offices, and community clinics. By engaging a variety of stakeholderspatients, families, providers, and researchers-PCORnet empowers individuals and organizations to use these data to answer practical questions that help patients, clinicians, and other stakeholders make informed health care decisions." 21 Phase II of ADVANCE through PCORnet seeks to expand on its phase I goals of expanding our stakeholder engagement and community-academic partnerships; integrating outpatient, hospital, and community-level data into a single data management system; and build on our "community laboratory" of Federally Qualified Health Centers jointly created by our patient, clinician, and health system leader stakeholders. Our phase II project summary describes this effort as such: "The mission of the ADVANCE CDRN-a team of organizations from around the country-is to learn about how to improve the health of safety net patients, including people living in poverty, with little or no insurance … In the past, vulnerable patient populations have not been included in many studies. As a network of safety net clinics, ADVANCE is able to help bridge this gap. Patients, caregivers, and clinicians are helping guide the ADVANCE research plan, develop study questions and materials, and share findings. By taking part in ADVANCE projects, people have an opportunity to improve care for themselves, their families, and their communities." 22 The ADVANCE CDRN engages patients and other stakeholders through 4 groups: the OCHIN Patient Engagement Panel (PEP), the Clinic and Patient Engagement Workgroup (CAPE), the Community Research Outreach and Dissemination Program (CROP-D) and finally, the ADVANCE Advisory Council (AAC), which oversees all research conducted using the ADVANCE network, includes members from each of the ADVANCE data partners as well as patient (2) 
OCHIN PEP
Building on these early efforts, OCHIN established a PEP to include patient voices and perspectives. Appendix 1, supplemental Digital Content 1, http://links.lww.com/MLR/B456, describes the timeline of the PEP as part of the development of the OCHIN Practice-based Research Network (PBRN) and ADVANCE research network. The details of the steps we took to establish the PEP and our lessons learned are described in a prior publication. 23 Our founding PEP members codeveloped the selection process of additional members, compensation policy, recruitment methodologies, and health literacy review to materials. During ADVANCE phase I, the work of PEP was generally expanded to support research capacity building and the ADVANCE engagement framework was developed (see Fig. 1 ).
Currently, there are 18 active patient advisors on the PEP, representing diverse backgrounds and lived experiences across multiple states, urban/rural locations, races/ethnicities, ages, sex, and sexual orientations. Patient advisors provide ongoing guidance to improve research recruitment, retention, and transparency. Through ADVANCE, PEP members have increased their involvement as coinvestigators directly advising on prepared and/or submitted proposals (from 3 to 9 members advising on > 22 projects). One member also successfully received 2 PCORI Pipeline to Proposals Tier One and Tier Two awards and has been building a separate patient-led collaborative research team, which now is poised to begin developing the team's first comparative effectiveness research funding proposal(s). 24 
CAPE Workgroup
In June 2014 of ADVANCE phase I, the CAPE workgroup was created. The CAPE is a tactical group for identified operational, clinical, and informatics staff from ADVANCE organizations (eg, OCHIN; Health Choice Network; Fenway Health; Legacy; OHSU), OCHIN health systems clinical oversight, research team partners, and select patients from the PEP. The workgroup provides feedback on an ongoing basis and learn about the challenges and barriers around increasing patient portal adoption rates, enhancing patient engagement (via research projects, patient outreach strategies, and additional tools), building shared communication tools, and sharing best practices and success. Patient, clinician and health system leader advisors provide ongoing guidance to overcome barriers in expanding patient portal adoption and use, such as colearnings around health literacy, technology access in the safety net, Spanish-language resources, patient and clinic-facing instructional guides, and patient portal workflow development.
CROP-D
ADVANCE network infrastructure funding has allowed OCHIN to build the CROP-D as part of its operations model to support and extend its engagement work with stakeholders. Established toward the end of ADVANCE phase I, the CROP-D is tasked with: coordinating stakeholder engagement workgroups; developing protocols and tools to support member recruitment and participation in research projects; collecting data on member organizations' research priorities and involvement; and disseminating research activities. The CROP-D is staffed from a variety of OCHIN departments and roles, including an Engagement Coordinator, a Site Principal Investigator, a Practice Facilitator, a Research Associate and an Account Manager.
PBRN
THE ADVANCE PBRN, established in 2007, is housed at OCHIN to maximize its independence and focus on community-based research. Members include network clinicians and operational staff, patient advisors, and research leadership to provide evaluation and assessment for our research endeavors. Members review proposals, share models and methodologies, and disseminate findings.
AAC
Early in ADVANCE phase I, the AAC was created to review and approve ADVANCE-specific policies, serve as the review board for any potential proposal, project, or data request utilizing ADVANCE, and develop and prioritize the ADVANCE research agenda. This model of shared decisionmaking is similar to that of the OCHIN and Health Choice Network community Boards of Directors. To ensure that ADVANCE is well integrated and attached to OCHIN's formal governance structure, the Advisory Council is integrated directly into the organizational structure of the OCHIN Board of Directors, as encouraged by OCHIN's bylaws for all projects of significance to OCHIN's members. The Advisory Council includes representatives from each of the ADVANCE data partners (further described above), as well as patient and clinician representatives.
ADVANCE Engagement Framework
ADVANCE currently uses a 3-level framework to guide and prioritize our strategies for engagement, jointly developed from our early PEP work and our patient, clinician and health system leader stakeholders (Fig. 1) . We actively recruit patients as investigators to advise and inform all aspects of ADVANCE (engagement level 1). We expanded the PEP, created a CAPE workgroup, and recruited patient representatives for the AAC and PBRN (engagement level 2). To further increase our ability to reach, inform, and engage more patients (engagement level 3), patient advisors offer ongoing guidance for the development and implementation of enhanced electronic tools for patients (eg, patient portals, websites, social media). Each of these groups serves an important purpose in bringing the voices of our key patient stakeholders into institutional strategies and leadership structures, and OCHIN has a dedicated budget for patient engagement activities.
IMPACT OF ENGAGEMENT
Through the initial creation of our engagement groups and framework described above through ADVANCE phase I, we developed the structure in which to involve a diverse group of patients in the design, implementation, and interpretation of comparative effectiveness research. As we were awarded phase II funding, we were able to build further on our stakeholder-identified engagement priorities of training, dissemination, and our ambassador program.
PHASE I ENGAGEMENT Designing Studies
In the PEP and CAPE through level 2 of our engagement framework, patient investigators reviewed and edited insurance support tools from a patient perspective, engaging in 4 project phases: proposal development; adapting study methods; understanding the context and tool testing; and implementation. 25 PEP guidance has resulted in a change of a proposal's primary outcome measure following stakeholder investigator calls and proposal reviews, as well as guidance from presentation at the PEP. ADVANCE patient investigator guidance (through level 1) resulted in changes to proposal methodology, such as the addition of domains and enhanced frequency of patient-reported outcome (PRO) measures to include pretreatment and posttreatment. In addition, through this same study, patient investigator guidance on the level of burden that patients with the condition of study, shared by the patient investigator, might be willing to accept (from a 5 to a 40-min PRO screening) supported a confirmation of retaining the initial length of the screening. This was augmented by the patient investigator stating that "those with a hard-to-treat disease would be more than willing to spend the extra time if they knew they were potentially contributing to better cures."
Usability Testing
Patient advisors codeveloped ADVANCE engagement level 3 activities. These included a clinical health survey (also assessing research interest) conducted across OCHIN clinics via patient portal; survey data included over 13,280 patient respondents, a response rate of 20% of all active patients (signed in at least once) on the portal. Patient advisors conducted rigorous usability testing, resulting in recommendations to make the survey more visible and its purpose more relevant for patients. Patient advisors have also guided layout and workflows for new PRO tools such as Screening, Brief Intervention, Referral to Treatment (SBIRT), 26 Patient Health Questionnaire (PHQ), 27 and the Patient-reported Outcomes Measurement Information System (PROMIS). 28 These advisors are contributing to the development of best practices to increase patient portal adoption and other patient engagement communication strategies (eg, text messaging, social media). For example, to capture valid patient responses, a patient investigator advised on ADVANCE and the SBIRT tool within the patient portal. This specific guidance resulted in the removal of the tool's scoring layout from the patient portal view and created a new best practice.
PHASE II ENGAGEMENT
On the basis of the feedback from ADVANCE's community-academic partnerships and a proposal developed and approved by PEP members, the AAC-approved engagement priorities are as follows: training, ambassador program, dissemination, and evaluation. These priorities are shaping ADVANCE engagement activities throughout phase II.
Training
This priority includes training resources for all stakeholders. In response, ADVANCE has purchased the CITI Program Training for Responsible Conduct of Research 29 for utilization by all stakeholder groups. The CROP-D is currently working with the PEP to facilitate their completion of the CITI training module and certification. Through an environmental scan of the available research trainings recommended from PCORI, our stakeholders and research staff, we assessed several options and determined that CITI training most closely aligned with our gaps in understanding, as well as our requirements for lnstitutional Review Board and human subject's protection processes. PEP patient leaders are also codeveloping training resources) in partnership with OCHIN's training subject matter experts and partner PCORnet CDRNs to be provided via web (websites, videos) and in person.
Ambassador Program
Our PEP and PBRN engagement structures are expanding their outreach through utilization of an ambassador program. Working with the Oregon Clinical and Translational Research Institute (OCTRI) and its framework for advocacy within community advisory boards, we have begun to recruit more PEP/PBRN members and coinvestigators and broadened our outreach to patients in the larger communities in which OCHIN member sites serve. We recently used this peer-to-peer program to engage a non-ADVANCE affiliated patient with a specific opioid-treatment background into an ADVANCE research proposal as a new patient coinvestigator. In this case, an established ADVANCE patient investigator co-led the successful recruitment effort for this role in collaboration with the network's engagement coordinator.
This veteran patient investigator provided initial outreach for an introductory phone call between the prospective patient investigator and the research proposal's principal investigator and team and continued support to build rapport and trust. In addition, through the veteran patient investigator's prior experiences around development of proposal materials (letter of support, biosketch), they were able to provide guidance in the new patient investigator's completion of these items. Although the proposal was unfortunately not funded, the inclusion of this new patient investigator, who shared personal experiences living with this condition, provided valuable guidance on the proposal's methodology and recruitment strategies, and powerfully strengthened the significance section of the final submission.
Dissemination
Within the engagement priority of enhanced dissemination, the ADVANCE team focused on efficient and effective ways to widely disseminate PBRN research findings. This is seen by our network stakeholders as a critical component for accelerating the translation of research into practice. Social media strategies, including podcasts and blogging, have the potential to augment the reach of research beyond traditional publication venues. 30 The founding patient member of the PEP was a featured patient ambassador author on the PCORI national blog, where she described the influence that PCORI has had on the work of ADVANCE and her perspectives on clinical research. In the post, the patient member and caregiver talks about how she got involved in her local health system, then state policy, and most recently ADVANCE as a part of PCORnet. 31 Although development continues in these expanded dissemination efforts, we learned that they require thoughtful efforts-finding stories for blogs and podcasts that complement scholarly publications and using these social media posts to communicate findings about recently published papers to broad community and patient audiences.
Patient coauthors have advised, guided, and been published on accepted manuscripts, including key reviews and contributions from PEP member coauthors with lived experience of the condition of study. 32 Patient investigators have presented at national and international conferences and coauthored research proposals and manuscripts. 33, 34 ADVANCE patient and clinician leaders recently acted as copresenters in the 2016 OCHIN Learning Forum (a national conference), with 5 PEP members and 2 PBRN steering committee members supporting 5 panels covering the impacts of the Affordable Care Act, stakeholder engagement, patient portal adoption, and enhancement and the OpenNotes movement, which provides patient access to visit notes through their patient portal. 35 
Evaluation
The ADVANCE 3-level engagement framework, developed with key input from many different stakeholders, serves as a guide for evaluating our patient engagement approaches. The network has been developing formal measures of engagement to track our activities and their impacts. Through an iterative process with the CROP-D and OCHIN research leadership, a number of process and board-reported measures were determined to evaluate our progress with engagement efforts. These measures include: the number of OCHIN member organizations actively involved in research projects, tracking the involvement of stakeholder workgroups in research activities (eg, the number of proposals and projects reviewed in partnership with stakeholder groups, the number of clinician and patient investigators named on research proposals and projects), and the centralization of tools and protocols for clinic and patient recruitment. In addition, the CROP-D is responsible for reaching the engagement-related funder milestones for the ADVANCE network.
Our ADVANCE team and stakeholders continually look to refine our metrics on what constitutes "successful engagement" and how we approach this process differently based on the audience. Our stakeholder (eg, patient, clinician, health system leader) engagement is evaluated within our ADVANCE team through both process measures (eg, attendance; number of coinvestigators) as well as outcome measures, such as documenting patient testimonials on the value of research engagement (Table 1) , tracking patient guidance provided to aspects of network activities, and in what capacity feedback has impacted projects throughout the research lifecycle.
For the development of outcome measures, patient advisors are asked to complete quarterly surveys soliciting the value of research engagement, identify any barriers and make recommendations to enhance their roles within the ADVANCE network. The development of these metrics are influenced through the PCORI Engagement Rubric, which provides key examples of "successful engagement" activities through each step of the research lifecycle. 36 
DISCUSSION
ADVANCE has successfully involved a diverse group of patients in the design, implementation, and interpretation of our research, making progress in 3 levels of engagement. As noted by our patient investigators, we have seen the importance of continuing to expand and improve on this work. Our PEP founding member and coauthor Kay Dickerson states, "My focus is doing all I can to bring affordable health care to all poor and underserved people. As a Hurricane Katrina survivor, I have personally known too many people pass away due to inadequate health care." ADVANCE patient investigator and coauthor Sele D'Amato further illustrates the need for this work, stating, "As an African American woman representing patients whose voice has not been heard often We know all-too-well the risks and dangers of health problems getting out-of-control. My sister and I often say that "we want to manage our diabetes instead of letting our diabetes manage us." This begins by helping clinic staff and doctors so they can help their patients. As an African American woman representing patients whose voice has not been heard often enough, I'm also very interested in advocating for more effective care that can reach patients who represent diversity of race, ethnicity, socioeconomic status, language, geography, sex, and education Kathy Norman ADVANCE Patient Investigator I believe that doctors are only able to do their jobs to their best when patients feel free and supported to have frank discussions. And, I believe this will require a lot of patient education especially in our older communities. An active patient voice just makes sense as a way to improve patient care enough, I'm also very interested in advocating for more effective care that can reach patients who represent diversity of race, ethnicity, socioeconomic status, language, geography, sex, and education." Through our phase II priorities, we further expanded our engagement of stakeholders through our ambassador model, building on the diversity of the network's patient advisor base. With enhanced training resources and research partner mentorship, we have able to build the skills, experience, and expertise of our patient investigators, advisors and patient members of our PEP, CAPE, and other engagement groups. Our codeveloped engagement polices around compensation, patient investigator roles, and PEP member responsibilities bring an enhanced level of respect to these positions and also streamline our network's ability to extend these roles to project-specific engagement opportunities.
Future Work
Using our 3 engagement priorities of training, the ambassador program and dissemination, future directions in meaningful patient engagement for our network will include the development of mechanisms to engage more patients with minimal burden (eg, brief online surveys), shared strategies to enhance working across a national collaborative, more consistent, relevant, and ongoing training for patient coinvestigators, and expanding toward more comprehensive and active collection of PROs via patient portals and other bidirectional communication methods to provide "real-time" support for clinical care. These additional efforts may further increase patient engagement in research that impacts health care delivery and health outcomes.
